USA Endometrial Cancer Projections to 2030: Should we be concerned?

Future Oncology

Volumn 10, Issue 16, 2014, Pages 2561-2568

  Sheikh, M Aamir ^a   Althouse, Andrew D ^a   Freese, Kyle E ^a,b   Soisson, Sean ^c   Edwards, Robert P ^a   Welburn, Sharon ^b   Sukumvanich, Paniti ^d   Comerci, John ^d   Kelley, Joseph ^d   Laporte, Ronald E ^b   Linkov, Faina ^a,b  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF PITTSBURGH GRADUATE SCHOOL OF PUBLIC HEALTH   (United States)

^c UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

Author keywords

endometrial cancer; future projections; incidence; obesity; prevention

Indexed keywords

AGED; ARTICLE; CANCER INCIDENCE; ENDOMETRIUM CANCER; FEMALE; HUMAN; HYSTERECTOMY; LINEAR REGRESSION ANALYSIS; MULTIVARIATE ANALYSIS; OBESITY; PREVALENCE; RISK FACTOR; SMOKING; UNITED STATES;

EID: 84919784600     PISSN: 14796694     EISSN: 17448301     Source Type: Journal    
DOI: 10.2217/fon.14.192     Document Type: Article

References (60)

1. Sorosky JI. Endometrial cancer. Obstet. Gynecol. 120(2 Pt 1), 383-397 (2012).
2. ACS. What are the key statistics about endometrial cancer. www.cancer.org
3. Reeves KW, Carter GC, Rodabough RJ et al. Obesity in relation to endometrial cancer risk and disease characteristics in the Women's Health Initiative. Gynecol. Oncol. 121(2), 376-382 (2011).
4. Vucenik I, Stains JP. Obesity and cancer risk: Evidence, mechanisms, and recommendations. Ann. N. Y. Acad. Sci. 1271, 37-43 (2012).
5. Wang D, Dubois RN. Associations between obesity and cancer: The role of fatty acid synthase. J. Natl Cancer Instit. 104(5), 343-345 (2012).
6. Wang D, Zheng W, Wang SM et al. Estimation of cancer incidence and mortality attributable to overweight, obesity, and physical inactivity in China. Nutr. Cancer 64(1), 48-56 (2012).
7. Calle EE, Rodriguez C, Walker-Thurmond K, Thun MJ. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N. Engl. J. Med. 348(17), 1625-1638 (2003).
8. Cook WN, Doherty, JA, Chen C. Endometrial Cancer (3rd Edition). D Schottenfeld JF (Ed.). Oxford University Press, NY, USA (2006).
9. Crosbie EJ, Zwahlen M, Kitchener HC, Egger M, Renehan AG. Body mass index, hormone replacement therapy, and endometrial cancer risk: A meta-Analysis. Cancer Epidemiol. Biomarkers Prev. 19(12), 3119-3130 (2010).
10. Chang SC, Lacey JV Jr, Brinton LA et al. Lifetime weight history and endometrial cancer risk by type of menopausal hormone use in the NIH-AARP diet and health study. Cancer Epidemiol. Biomarkers Prev. 16(4), 723-730 (2007).
11. Stevens VL, Jacobs EJ, Patel AV, Sun J, Gapstur SM, McCullough ML. Body weight in early adulthood, adult weight gain, and risk of endometrial cancer in women not using postmenopausal hormones. Cancer Causes Control 25(3), 321-328 (2014).
12. Esposito K, Chiodini P, Capuano A, Bellastella G, Maiorino MI, Giugliano D. Metabolic syndrome and endometrial cancer: A meta-Analysis. Endocrine 45(1), 28-36 (2014).
13. Weiderpass E, Persson I, Adami HO, Magnusson C, Lindgren A, Baron JA. Body size in different periods of life, diabetes mellitus, hypertension, and risk of postmenopausal endometrial cancer (Sweden). Cancer Causes Control 11(2), 185-192 (2000).
14. Schouten LJ, Goldbohm RA, van den Brandt PA. Anthropometry, physical activity, and endometrial cancer risk: Results from the Netherlands cohort study. Int. J. Gynecol. Cancer 16(Suppl. 2), 492 (2006).
15. Setiawan VW, Yang HP, Pike MC et al. Type I and II endometrial cancers: Have they different risk factors? J. Clin. Oncol. 31(20), 2607-2618 (2013).
16. Modugno F, Ness RB, Chen C, Weiss NS. Inflammation and endometrial cancer: A hypothesis. Cancer Epidemiol. Biomarkers Prev. 14(12), 2840-2847 (2005).
17. Zhou B, Yang L, Sun Q et al. Cigarette smoking and the risk of endometrial cancer: A meta-Analysis. Am. J. Med. 121(6), 501-508 e3 (2008).
18. Renehan AG, Roberts DL, Dive C. Obesity and cancer: Pathophysiological and biological mechanisms. Arch. Physiol. Biochem. 114(1), 71-83 (2008).
19. Ziel HK. Estrogen's role in endometrial cancer. Obstet. Gynecol. 60(4), 509-515 (1982).
20. Key TJ, Pike MC. The dose-effect relationship between 'unopposed' oestrogens and endometrial mitotic rate: Its central role in explaining and predicting endometrial cancer risk. Br. J. Cancer 57(2), 205-212 (1988).
21. Judd HL, Davidson BJ, Frumar AM, Shamonki IM, Lagasse LD, Ballon SC. Serum androgens and estrogens in postmenopausal women with and without endometrial cancer. Am. J. Obstet. Gynecol. 136(7), 859-871 (1980).
22. Gambrell RD Jr, Bagnell CA, Greenblatt RB. Role of estrogens and progesterone in the etiology and prevention of endometrial cancer: Review. Am. J. Obstet. Gynecol. 146(6), 696-707 (1983).
23. Kaaks R, Lukanova A, Kurzer MS. Obesity, endogenous hormones, and endometrial cancer risk: A synthetic review. Cancer Epidemiol. Biomarkers Prev. 11(12), 1531-1543 (2002).
24. Dossus L, Lukanova A, Rinaldi S et al. Hormonal, metabolic, and inflammatory profiles and endometrial cancer risk within the EPIC cohort-A factor analysis. Am. J. Epidemiol. 177(8), 787-799 (2013).
25. Crosbie EJ, Roberts C, Qian W, Swart AM, Kitchener HC, Renehan AG. Body mass index does not influence post-Treatment survival in early stage endometrial cancer: Results from the MRC ASTEC trial. Eur. J. Cancer 48(6), 853-864 (2012).
26. Linkov F, Taioli E. Factors influencing endometrial cancer mortality: The Western Pennsylvania Registry. Future Oncol. 4(6), 857-865 (2008).
27. Linkov F, Edwards R, Balk J et al. Endometrial hyperplasia, endometrial cancer and prevention: Gaps in existing reseArch. of modifiable risk factors. Eur. J. Cancer 44(12), 1632-1644 (2008).
28. Felix AS, Weissfeld JL, Stone RA et al. Factors associated with type I and type II endometrial cancer. Cancer Causes Control 21(11), 1851-1856 (2010).
29. Setiawan VW, Yang HP, Pike MC et al. Type I and II endometrial cancers: Have they different risk factors? J. Clin. Oncol. 31(20), 2607-2618 (2013).
30. Dossus L, Allen N, Kaaks R et al. Reproductive risk factors and endometrial cancer: The European Prospective Investigation into Cancer and Nutrition. Int. J. Cancer 127(2), 442-451 (2010).
31. Jones ME, van Leeuwen FE, Hoogendoorn WE et al. Endometrial cancer survival after breast cancer in relation to tamoxifen treatment: Pooled results from three countries. Breast Cancer Res. 14(3), R91 (2012).
32. Wartko P, Sherman ME, Yang HP, Felix AS, Brinton LA, Trabert B. Recent changes in endometrial cancer trends among menopausal-Age U.S. women. Cancer Epidemiol. 37(4), 374-377 (2013).
33. Go AS, Mozaffarian D, Roger VL et al. Heart disease and stroke statistics-2013 update: A report from the American Heart Association. Circulation 127(1), e6-e245 (2013).
34. Bianchini F, Kaaks R, Vainio H. Overweight, obesity, and cancer risk. Lancet Oncol. 3(9), 565-574 (2002).
35. Reeves GK, Pirie K, Beral V, Green J, Spencer E, Bull D. Cancer incidence and mortality in relation to body mass index in the Million Women Study: Cohort study. BMJ 335(7630), 1134 (2007).
36. von Gruenigen VE, Gil KM, Frasure HE, Jenison EL, Hopkins MP. The impact of obesity and age on quality of life in gynecologic surgery. Am. J. Obstet. Gynecol. 193(4), 1369-1375 (2005).
37. Smith BD, Smith GL, Hurria A, Hortobagyi GN, Buchholz TA. Future of cancer incidence in the United States: Burdens upon an aging, changing nation. J. Clin. Oncol. 27(17), 2758-2765 (2009).
38. Bray F, Moller B. Predicting the future burden of cancer. Nat. Rev. Cancer 6(1), 63-74 (2006).
39. Jamison PM, Noone AM, Ries LA, Lee NC, Edwards BK. Trends in endometrial cancer incidence by race and histology with a correction for the prevalence of hysterectomy, SEER 1992 to 2008. Cancer Epidemiol. Biomarkers Prev. 22(2), 233-241 (2013).
40. Census. Population Estimates. United States Census. www.census.gov/
41. Finkelstein EA, Khavjou OA, Thompson H et al. Obesity and severe obesity forecasts through 2030. Am. J. Prev. Med. 42(6), 563-570 (2012).
42. Trends in Tobacco US American Lung Association. www.lung.org
43. Whiteman MK, Hillis SD, Jamieson DJ et al. Inpatient hysterectomy surveillance in the United States, 2000-2004. Am. J. Obstet. Gynecol. 198(1), 34 e1-7 (2008).
44. Merrill RM. Hysterectomy surveillance in the United States, 1997 through 2005. Med. Sci. Monit. 14(1), CR24-CR31 (2008).
45. Farquhar CM, Steiner CA. Hysterectomy rates in the United States 1990-1997. Obstet. Gynecol. 99(2), 229-234 (2002).
46. Wright JD, Herzog TJ, Tsui J et al. Nationwide trends in the performance of inpatient hysterectomy in the United States. Obstet. Gynecol. 122(2 Pt 1), 233-241 (2013).
47. Walker AM, Jick H. Temporal and regional variation in hysterectomy rates in the United States, 1970-1975. Am. J. Epidemiol. 110(1), 41-46 (1979).
48. Jick H WA, Rothman KJ. The epidemic of endometrial cancer: A commentary. Am. J. Public Health 70(3), 264-267 (1980).
49. Siegel RL, Devesa SS, Cokkinides V, Ma J, Jemal A. State-level uterine corpus cancer incidence rates corrected for hysterectomy prevalence, 2004 to 2008. Cancer Epidemiol. Biomarkers Prev. 22(1), 25-31 (2013).
50. Yancik R. Population aging and cancer: A cross-national concern. Cancer J. 11(6), 437-441 (2005).
51. Ries LAG, Young JL Jr, Keel GE, Eisner MP, Lin YD, Horner M-JD. Cancer survival among adults: US SEER program, 1988-2001. Patient and tumor characteristics SEER Survival Monograph Publication. 07-6215 2007. http://seer.cancer.gov
52. Brown ML, Riley GF, Schussler N, Etzioni R. Estimating health care costs related to cancer treatment from SEER-Medicare data. Med. Care 40(8 Suppl.), IV-104-IV-117 (2002).
53. Cawley J, Meyerhoefer C. The medical care costs of obesity: An instrumental variables approach. J. Health Econ. 31(1), 219-230 (2012).
54. Argenta PA, Kassing M, Truskinovsky AM, Svendsen CA. Bariatric surgery and endometrial pathology in asymptomatic morbidly obese women: A prospective, pilot study. BJOG 120(7), 795-800 (2013).
55. Argenta P, Svendsen C, Elishaev E et al. Hormone receptor expression patterns in the endometrium of asymptomatic morbidly obese women before and after bariatric surgery. Gynecol. Oncol. 133(1), 78-82 (2014).
56. Benshushan A, Paltiel O, Rojansky N, Brzezinski A, Laufer N. IUD use and the risk of endometrial cancer. Eur. J. Obstet. Gynecol. Reprod. Biol. 105(2), 166-169 (2002).
57. Montz FJ, Bristow RE, Bovicelli A, Tomacruz R, Kurman RJ. Intrauterine progesterone treatment of early endometrial cancer. Am. J. Obstet. Gynecol. 186(4), 651-657 (2002).
58. Purdie DM, Green AC. Epidemiology of endometrial cancer. Best Pract. Res. Clin. Obstet. Gynaecol. 15(3), 341-354 (2001).
59. Sankaranarayanan R, Ferlay J. Worldwide burden of gynaecological cancer: The size of the problem. Best Pract. Res. Clin. Obstet. Gynaecol. 20(2), 207-225. (2006).
60. Mistry M, Parkin DM, Ahmad AS, Sasieni P. Cancer incidence in the United Kingdom: Projections to the year 2030. Br. J. Cancer 105(11), 1795-1803 (2011).